PlainPharmaWatch

CMS Open Payments · Tool

Astellas Pharma Inc vs Aptis Medical, LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Aptis Medical, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 9,916, versus 2,312 for the other company. Its single largest recorded recipient represents 99.6% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Astellas Pharma Inc
HHI 2,312 · top recipient 31.7%
Ranked #693 of 1,838 companies by HHI
Aptis Medical, LLC
HHI 9,916 · top recipient 99.6%
Ranked #136 of 1,838 companies by HHI

Payment Overview

Total Payments
$6.9M
% of Industry
0.0%
Transactions
2,831
Avg per Transaction
$2.4K
Recipients
81
Avg per Recipient
$85.1K
Payment Types
4
Top Payment Type
Travel and Lodging
Company B

Aptis Medical, LLC

Total Payments
$6.8M
% of Industry
0.0%
Transactions
98
Avg per Transaction
$69.3K
Recipients
95
Avg per Recipient
$71.4K
Payment Types
4
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Astellas Pharma Inc vs Aptis Medical, LLC - total reported payments in CMS Open Payments PY2024

Astellas Pharma Inc$6.9MAptis Medical, LLC$6.8M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Astellas Pharma Inc

Travel and Lodging $51.9K

62.7%

Compensation for Services Other Than Consulting $21.2K

25.7%

Consulting Fee $5.8K

7.0%

Food and Beverage $3.9K

4.7%

Aptis Medical, LLC

Royalty or License $948.2K

79.1%

Consulting Fee $183.5K

15.3%

Travel and Lodging $48.5K

4.0%

Food and Beverage $18.6K

1.6%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Astellas Pharma Inc

  1. 1

    MARK LEVIS

    $26,221.48 · 9 txns

  2. 2

    SANDIP VASAVADA

    $21,158.17 · 4 txns

  3. 3

    TERENCE FRIEDLANDER

    $20,630.87 · 14 txns

  4. 4

    LINDA CRIPE

    $3,520.00 · 4 txns

  5. 5

    NAVAL DAVER

    $1,691.23 · 2 txns

Aptis Medical, LLC

  1. 1

    LUIS SCHEKER

    $1,193,816.79 · 89 txns

  2. 2

    PAUL SIBLEY

    $4,367.68 · 3 txns

  3. 3

    ALEXANDER SHIN

    $501.00 · 2 txns

  4. 4

    MIGUEL PIRELA-CRUZ

    $177.00 · 1 txns

Summary Comparison

Metric Astellas Pharma Inc Aptis Medical, LLC
Total Payments $6.9M $6.8M
% of Industry Total 0.0% 0.0%
Transaction Count 2,831 98
Avg per Transaction $2.4K $69.3K
Recipient Count 81 95
Avg per Recipient $85.1K $71.4K
Payment Type Count 4 4
Top Payment Type Travel and Lodging Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.